Article Text

Download PDFPDF
Long-term follow-up confirms a survival advantage of the paclitaxel–cisplatin regimen over the cyclophosphamide–cisplatin combination in advanced ovarian cancer
  1. M. J. Piccart*,
  2. K. Bertelsen,
  3. G. Stuart,
  4. J. Cassidy§,
  5. C. Mangioni*,
  6. E. Simonsen,
  7. K. James,
  8. S. Kaye§,
  9. I. Vergote*,
  10. R. Blom,
  11. R. Grimshaw,
  12. R. Atkinson§,
  13. K. Swenerton,
  14. C. Trope,
  15. M. Nardi*,
  16. J. Kaern,
  17. S. Tumolo*,
  18. P. Timmers*,
  19. J.-A. Roy*,
  20. F. Lhoas*,
  21. B. Lidvall,
  22. M. Bacon,
  23. A. Birt§,
  24. J. Andersen,
  25. B. Zee,
  26. J. Paul§,
  27. S. Pecorelli*,
  28. B. Baron* and
  29. W. Mcguire
  1. * EORTC Gynecological Cancer Cooperative Group, Brussels, Belgium
  2. Nordic Society of Gynecologic Oncology Data Centre, Odense University Hospital, Odense, Denmark
  3. National Cancer Institute of Canada Clinical Trials Group Data Center-Queen's University, Kingston, Ontario, Canada
  4. § Scottish Group Data Centre, Beatson Oncology Centre, Western Infirmary, Glasgow, UK
  5. Gynecologic Oncology Group, Baltimore, MD, USA
  1. Address correspondence and reprint requests to: Martine J. Piccart, MD, Jules Bordet Institute, Chemotherapy Unit, Rue Heger-Bordet, 1, 1000 Brussels, Belgium. Email: martine.piccart{at}


Two independent and consecutive randomized clinical trials, conducted by the American Gynecological Oncology Group and by an European–Canadian Intergroup, have shown superiority, in clinical response rate, progression-free survival, and overall survival, of a cisplatin–paclitaxel regimen over cisplatin–cyclophosphamide given as first-line chemotherapy for women with advanced epithelial ovarian cancer. The results of these studies, published with a median follow-up of about 3 years, have been updated with a 6.5-year follow-up: In each case, an 11% absolute gain in survival favoring the paclitaxel arm is shown; this advantage remains both statistically and clinically significant and supports a role for paclitaxel in frontline chemotherapy for advanced ovarian cancer.

  • advanced stage
  • chemotherapy
  • cisplatin
  • ovarian neoplasm
  • paclitaxel

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.